Human T-cells use T-cell receptors to eliminate diseased cells. This natural phenomenon can be harnessed for the development of TCR-based therapies to eradicate solid tumors. However, safe, high-affinity TCRs against cancer targets are rare and hard to identify using traditional wet-lab methods.
Our generative AI platform enables comprehensive mining of the TCR sequence space to discover completely novel, high-affinity and non-cross-reactive TCRs against targets shared across patients and tumor types.
Global Roundup: Exogene Secures Funding to Support TCR Discovery
April 28th, 2022
U.K.-based Exogene, which is developing novel T-cell receptor-based cell therapies, secured $2 million in new funding to help advance the development of its artificial intelligence (AI) platform for T-cell receptor discovery…